Related Experiment Videos
Epitope- and antigen-specific cancer vaccines
D Herlyn1, A Linnenbach, H Koprowski
1Wistar Institute of Anatomy and Biology, Philadelphia, PA 19104.
International Reviews of Immunology
|January 1, 1991
Summary
Anti-idiotypic antibodies (Ab2) and recombinant antigens (Ag) show promise as cancer vaccines. Both can induce anti-tumor immunity, but their comparative effectiveness in patients requires further study.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Anti-idiotypic antibodies (Ab2) mimic cancer cell epitopes and induce humoral anti-tumor immunity.
- The capacity of Ab2 to induce cellular immunity in cancer patients remains to be demonstrated.
- Molecularly cloned tumor-associated antigens (Ag) represent a new generation of cancer vaccines.
Purpose of the Study:
- To evaluate the potential of Ab2 and recombinant Ag as cancer vaccines.
- To compare the immunogenicity of Ab2 and recombinant Ag.
- To explore the induction of cellular immunity against cancer.
Main Methods:
- Development of Ab2 that mimic tumor-associated epitopes.
- Large-scale production and expression of recombinant tumor-associated antigens (Ag).
- Immunization studies in experimental animals to assess immune responses.
Main Results:
- Ab2 can induce specific humoral anti-tumor immunity.
- Recombinant Ag have been successfully produced and shown to induce specific, protective immunity in animals.
- Recombinant Ag express multiple epitopes, potentially offering broader immunogenicity than single-epitope Ab2.
Conclusions:
- Both Ab2 and recombinant Ag show potential for cancer vaccination by inducing specific B and T cell immunity in preclinical models.
- Recombinant Ag may be more effective than Ab2 due to multi-epitope presentation.
- Further comparative studies in cancer patients are needed to determine the optimal vaccine strategy.